Qiagen’s operating income for the full year stood at $630m. Credit: QIAGEN / Flickr.

Qiagen has reported a 20% increase in full-year 2021 net sales at constant exchange rates (CER) to $2.25bn, as against $1.87bn in 2020.

High demand for Covid-19 test products and confirmed positive trends in the non-Covid portfolio contributed to the rise in sales.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Adjusted diluted EPS during the period increased 23% to $2.65, compared to $2.15 in the prior year.

The company’s operating income for the full year stood at $630m, as against $386m in 2020, representing a 63% increase.

Qiagen CEO Thierry Bernard said: “Our very solid results in the fourth quarter capped a tremendous year for Qiagen, especially the 22% CER growth in our non-Covid product portfolio that has consistently outperformed.

“Going into 2022, we are optimistic about opportunities in the research environment amid healthy increases in national funding programmes, as well as robust trends in regular clinical testing for molecular diagnostics.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

In the US 25% CER growth was delivered for the full year, benefiting from significant gains in non-Covid product group sales, particularly QuantiFERON and QIAcuity, while sales related to Covid-19 grew at a mid-single-digit CER rate.

In Europe, significant gains were delivered in Austria, the UK, Italy, Turkey and Switzerland and were complemented by single-digit CER growth in France.

Qiagen sales in China increased above 20% CER for the full year and at a mid-single-digit CER rate in the fourth quarter.

For the fourth quarter (Q4) of 2021, the company’s net sales increased 2% CER to $582m, compared to $571m in 2020, and adjusted diluted EPS rose 9% to $0.74, as against $0.68 in the previous year.

Operating income during the quarter rose 11% to $173m, an increase from $156m in the year-ago period.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact